Segment Reporting
The Company manages its business activities on a consolidated basis and operates as a single operating segment: Biotechnology. The accounting policies of the Biotechnology segment are the same as those described in Note 2 – Summary of Significant Accounting Policies.
The Company’s chief operating decision maker (“CODM”) was Andy Yoo, its Director, President and Chief Executive Officer from December 2024 to February 2026. The CODM uses net loss, as reported on the Company’s Consolidated Statements of Comprehensive Income, in evaluating performance of the Biotechnology segment and determining how to allocate resources of the Company as a whole. The CODM does not review assets in evaluating the results of the Biotechnology segment, and therefore, such information is not presented.
The following table provides the operating financial results of our Biotechnology segment:
Year Ended
December 31,
20252024
Total revenues$— $500 
Significant segment expenses:
Research and development expense3,286 — 
General and administrative expense6,831 5,449 
Litigation legal expense— 1,562 
Right-of-use asset impairment loss— 5,721 
Loss from sale of property and equipment90 — 
Gain on early lease termination(5,974)— 
Total operating expenses4,233 12,732 
Interest and dividend income136 13 
Interest expense(1)(18)
Other income (expense), net71 2,544 
Change in fair value of contingent liability(1,553)— 
Total other income (expense)(1,347)2,539 
Segment net loss$(5,580)$(9,701)

Historical Timeline

Fiscal YearFiled
2025Mar 25, 2026Showing above
2024Mar 18, 2025

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.